Granules India Limited — Investor Meet, 05-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Granules India delivered a strong FY26, a "deliberate reset" year. Full-year revenue reached INR 5,365.6 Cr (+20% YoY), with Q4 revenue at INR 1,470.6 Cr (+23% YoY). FY26 EBITDA was INR 1,185.1 Cr (+25% YoY), and gross margins expanded to 65%. Net debt significantly reduced to INR 402.1 Cr.

The US generic business (GPI) is now #27 nationally, #4 in controlled substances. Senn Chemicals (CDMO) achieved positive Q4 EBITDA, a key growth driver, aiming for FY27 PAT positivity. Gagillapur remediation is complete, awaiting US FDA re-inspection. Outlook prioritizes FDA readiness, scaling new businesses, and complex products. Management is confident despite cost uncertainties.